Therapeutic and market expectancy of recombinant medicines
Komitet Biotechnologii PAN ; Instytut Chemii Bioorganicznej PAN
Therapeutic applications and global market of commercialized biopharmaceuticals-recombinant medicines have been presented. The first and second generation of genetically engineered products such as: hormones, cytokines, blood factors, monoclonal antibodies and others approved to date or undergoing clinical investigations in the US and EU have been described. They are used to treat or prevent many diseases, including: diabetes, growth deficiency, anemia, cardio-vascular disorders and, especially, immune-mediated inflammatory disorders and various cancers. The authors have also presented current global biopharmaceutical market, leading biopharmaceuticals, the fastest growing recombinant protein categories and strategic market analysis and forecasts until 2010.
Biotechnologia, vol.71, 4 (2005)-.
0860-7796 ; oai:rcin.org.pl:88585 ; IChB B-67
Biblioteka Instytutu Chemii Bioorganicznej PAN
Licencja Creative Commons Uznanie autorstwa-Na tych samych warunkach 4.0
Instytut Chemii Bioorganicznej Polskiej Akademii Nauk
Instytut Chemii Bioorganicznej Polskiej Akademii Nauk
Oct 2, 2020
Dec 17, 2019
1070
https://rcin.org.pl./publication/115438
Edition name | Date |
---|---|
Terapeutyczne i rynkowe perspektywy rekombinowanych leków | Oct 2, 2020 |
Borkowska, Bożenna
Ziółkowski, Piotr Babula- Skowrońska, Danuta Kaczmarek, Małgorzata Cieśla, Agata Sadowski, Jan
Nowak, Jacek K.